This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease

This study has been terminated.
(Discontinuation of drug supply from Astellas.)
Brigham and Women's Hospital
Astellas Pharma Inc
Information provided by (Responsible Party):
Corey S. Cutler, MD, MPH, Dana-Farber Cancer Institute Identifier:
First received: October 21, 2010
Last updated: August 11, 2013
Last verified: August 2013
Alefacept is a drug tht may reduce the number of T cells in circulation. This drug has been used in the treatment of psoriasis, which is a skin disorder also caused by T cells, like chronic GVHD. Information from studies in psoriasis and in other patients with GVHD suggests that this drug may help to treat chronic GVHD. Chronic GVHD is a medical condition that can develop after allogeneic stem cell transplantation. It occurs when the donor immune cells (the "graft") attack and damage organs and tissue (the "host"). It is thought that T cells, a subtype of immune cells, are responsible for the tissue damage in chronic GVHD. In this research study we are looking to see how well Alefacept works in treating chronic GVHD that has not resolved after therapy with corticosteroids.

Condition Intervention Phase
Chronic Graft-versus-host Disease Drug: Alefacept Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Open-Label, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease

Resource links provided by NLM:

Further study details as provided by Corey S. Cutler, MD, MPH, Dana-Farber Cancer Institute:

Primary Outcome Measures:
  • Efficacy [ Time Frame: 2 years ]
    Proportion of patients with a favorable response, defined as a complete or partial remission at week 12 as compared to baseline in subjects with steroid refractory cGVHD.

Secondary Outcome Measures:
  • Safety of Alefacept Infusions in Patients With Chronic GVHD. [ Time Frame: 2 years ]
    Assess the safety of alefacept in this patient population. The number of adverse events (including hematological and non-hematological safety events) will be used for safety assessment.

Enrollment: 6
Study Start Date: October 2010
Study Completion Date: August 2012
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Alefacept
Alefacept iv
Drug: Alefacept
Given intravenously Days 1 and 4 of Week 1, then subcutaneously once weekly for Weeks 2-12
Other Name: Amevive

Detailed Description:
  • During the first week of treatment, participants will receive 2 doses of Alefacept intravenously (Day 1 and Day 4). During weeks 2-12, Alefacept will be given subcutaneously once weekly.
  • On weeks 1, 2 and every other week through Week 12 of study treatment, participants will have a physical exam, blood tests, and be asked general health and specific questions about any problems they may be having.
  • Every other week, participants will be asked to complete a questionnaire about their physical symptoms, activity level and emotional well being.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age or older
  • Diagnosed with cGVHD according to NIH criteria
  • Active cGVHD despite treatment with corticosteroids AND one additional immunosuppressive agent for at least 4 weeks, within 52 weeks of enrollment.
  • Subject is a recipient of related or unrelated BMT or PBSCT
  • Subject underwent transplantation at least 6 months prior to enrollment
  • Subject is on stable immunosuppressive regimen for 2 weeks prior to enrollment. Adjustment of immunosuppressive medications to maintain a therapeutic level is permitted.
  • Female of child bearing potential must have a negative pregnancy test prior to first dose of alefacept and must agree to practice effective contraception during the study. Men must also agree to use adequate contraception prior to study entry and for the duration of the study.
  • Meets medication restriction requirements and agrees to follow medications restrictions during study.

Exclusion Criteria:

  • Received donor lymphocyte infusions in the preceding 100 days
  • Currently undergoing ECP
  • Subject is recipient of related or unrelated UCB
  • Subject has bronchiolitis obliterans, bronchiolitis obliterans with organizing pneumonia or cryptogenic organizing pneumonia as the sole manifestation of cGVHD
  • Uncontrolled intercurrent active infection.
  • Absolute neutrophil count < 1000/L
  • AST, ALT or total bilirubin > 2x institutional upper limit of normal unless this is a manifestation of GVHD
  • Recurrent or progressive malignancy at any time after HCT, as applicable for the individual malignancy
  • Subject was in any clinical study within the last 30 days
  • Receipt of 5 or more prior agents to treat cGVHD
  • Known hypersensitivity to alefacept or any components of the study medication
  • Known to be positive for human immunodeficiency virus (HIV) antibodies
  • Currently enrolled in any other study for chronic GVHD treatment and receiving treatment under the study or previous participation in this study.
  • Pregnant or nursing
  • Concurrent illness which, in the opinion of the Investigator, may interfere with treatment or evaluation of safety
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01226420

United States, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
United States, Washington
Fred Hutch Cancer Research Center
Seattle, Washington, United States, 98109-1024
United States, Wisconsin
Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Sponsors and Collaborators
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Astellas Pharma Inc
Principal Investigator: Corey Cutler, MD Dana-Farber Cancer Institute
  More Information

Responsible Party: Corey S. Cutler, MD, MPH, Principal Investigator, Dana-Farber Cancer Institute Identifier: NCT01226420     History of Changes
Other Study ID Numbers: 10-230
Study First Received: October 21, 2010
Results First Received: January 28, 2013
Last Updated: August 11, 2013

Keywords provided by Corey S. Cutler, MD, MPH, Dana-Farber Cancer Institute:

Additional relevant MeSH terms:
Graft vs Host Disease
Immune System Diseases
Dermatologic Agents processed this record on September 20, 2017